Validation Data Gallery
Filter:
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
30466-1-PBS targets SLC16A13 in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag33183 Product name: Recombinant human SLC16A13 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 395-426 aa of BC142618 Sequence: FCFSTTTSGPQDLVTEALDTKVPLPKEGLEED 相同性解析による交差性が予測される生物種 |
| Full Name | solute carrier family 16, member 13 (monocarboxylic acid transporter 13) |
| Calculated molecular weight | 426 aa, 45 kDa |
| Observed molecular weight | 45-50 kDa |
| GenBank accession number | BC142618 |
| Gene Symbol | SLC16A13 |
| Gene ID (NCBI) | 201232 |
| RRID | AB_3086327 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q7RTY0 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
SLC16A13 (solute carrier family 16 member 13), which encodes the monocarboxylate transporter 13 (MCT13), is a susceptibility gene for type 2 diabetes and is expressed in the liver and duodenum (PMID: 37630718). SLC16A13 is a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (PMID: 34211098).